Evidence map›Paper›PMID 34292499›Full record

ArticleJournal of gastrointestinal cancer2022

Combination Therapy with KRAS and P38α siRNA Suppresses Colorectal Cancer Growth and Development in SW480 Cell Line.

Shiva Kamran, Ensiyeh Seyedrezazadeh, Dariush Shanehbandi, Milad Asadi, Venus Zafari, Najibeh Shekari, Leila Namvar, Habib Zarredar

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of gastrointestinal cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. miR-145 restoration overcomes oxaliplatin resistance via ABCC1 in colorectal cancer.Journal of the Egyptian National Cancer Institute · 2026
    Article
  3. Review
  4. Article
  5. Impact of KRAS mutation on the tumor microenvironment in colorectal cancer.International journal of biological sciences · 2024
    Review
  6. Article
  7. Review
  8. siRNA and targeted delivery systems in breast cancer therapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
    Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Shiva KamranTuberculosis and Lung Disease Research Center, Tabriz University of Medical Science, Tabriz, Iran.
Ensiyeh SeyedrezazadehTuberculosis and Lung Disease Research Center, Tabriz University of Medical Science, Tabriz, Iran.
Dariush ShanehbandiImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Milad AsadiImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Venus ZafariTuberculosis and Lung Disease Research Center, Tabriz University of Medical Science, Tabriz, Iran.
Najibeh ShekariDepartment of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Leila NamvarTuberculosis and Lung Disease Research Center, Tabriz University of Medical Science, Tabriz, Iran.
Habib ZarredarTuberculosis and Lung Disease Research Center, Tabriz University of Medical Science, Tabriz, Iran. Habib_Zarredar@yahoo.com.ORCID http://orcid.org/0000-0002-7217-7521
University of Tabriz · IRTabriz University of Medical Sciences · IRShahid Beheshti University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeColorectal cancer (CRC) is one of the most prevalence malignancies in a different society with a high rate of death. The KRAS and p38α axes have critical roles in the development, migration, and growth of numerous tumors, such as colorectal malignancy. KRAS mutation acts as an oncogene in various cancers and is correlated with the poor prognosis in colorectal tumors. Also, p38α plays different roles and exhibits tissue-dependent activity. In some tissues act as an oncogene while in others act as a tumor suppressor. In this research, we try to understand the effect of the P38α and KRAS genes suppression by specific siRNAs on the SW480 cell line progression.

methodsWe evaluate the impact of the P38α and KRAS gene knockdown by special siRNA on the growth and development of the SW480 cell line. SW480 cell line was treated with KRAS and P38α siRNAs, and the cell viability, gene expression, migration ability, and rate of apoptosis were evaluated with MTT assay, real-time PCR, scratch test, and flow cytometry.

resultsAfter treatment of the cancer cell with KRAs and P38α siRNAs, cell viability reduced to 29.16%. Also, the expression levels of the KRAS and P38α genes reduced to 26.34% and 16.06%, respectively. Apoptosis rate after combination therapy with KRAS and P38α siRNAs increased to 72.1. Also, we found that these siRNAs suppress cell migration in SW480 cell lines.

conclusionThe current study showed that combination therapy with p38α and KRAS siRNA may be considered a novel therapy for colorectal tumor in future.

Indexed as

Colorectal NeoplasmsProto-Oncogene Proteins p21(ras)ApoptosisCell Line, TumorCell ProliferationHumansMitogen-Activated Protein Kinase 14RNA, Small InterferingKRAS protein, humanMitogen-Activated Protein Kinase 14Proto-Oncogene Proteins p21(ras)RNA, Small InterferingColorectal cancerKRASP38siRNA

Identifiers

PMID34292499
OpenAlexW3183471774

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.